NRX Pharmaceuticals (Nasdaq:Nrxp) Announces Promising Findings in Phase 2B/3 Clinical Trial of NRX-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression
NRX Pharmicals(納斯達克股票代碼:Nrxp)宣佈 NRX-101 Vs. 2B/3 期臨床試驗的令人鼓舞的結果魯拉西酮用於治療自殺性雙相抑鬱症
NRX Pharmaceuticals (Nasdaq:Nrxp) Announces Promising Findings in Phase 2B/3 Clinical Trial of NRX-101 Vs. Lurasidone for Treatment of Suicidal Bipolar Depression
NRX Pharmicals(納斯達克股票代碼:Nrxp)宣佈 NRX-101 Vs. 2B/3 期臨床試驗的令人鼓舞的結果魯拉西酮用於治療自殺性雙相抑鬱症
使用瀏覽器的分享功能,分享給你的好友吧